Loading clinical trials...
Loading clinical trials...
Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized Phase III Study
Conditions
Interventions
Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
Locations
1
Germany
Pierre Fabre Pharma GmbH
Freiburg im Breisgau, Jechtinger Str. 13, Germany
Start Date
April 1, 2005
Primary Completion Date
September 1, 2011
Last Updated
October 4, 2016
NCT06305754
NCT07486219
NCT05098132
NCT06731413
NCT04585750
NCT05987644
Lead Sponsor
Pierre Fabre Medicament
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions